Cosmo Pharmaceuticals Announces Strong 2024 Revenue Growth and Pipeline Advancements
核心洞察
Cosmo Pharmaceuticals reported a 186% increase in full-year 2024 revenue, reaching €265.7 million, driven by collaborations and AI advancements in the GI Genius (搜索) platform.
The company's cash reserves reached €170.4 million by year-end, supported by strong operational performance and strategic investments, positioning Cosmo for sustained growth.
Key pipeline programs, including Winlevi for acne, Breezula for androgenetic alopecia (搜索), and treatments for Bile Acid Diarrhea (搜索) and Distal Ulcerative Colitis (搜索), are progressing with anticipated milestones in 2025 and 2026.
Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced strong preliminary unaudited 2024 revenue and year-end cash, highlighting exceptional revenue growth and a solid financial position. The company reported full-year revenue of €265.7 million, a 186% increase compared to 2023. Year-end cash and short-term investments reached €170.4 million, reflecting a robust balance sheet with zero debt.
Financial Highlights
The significant revenue increase includes €185 million in non-recurring revenues from Medtronic, linked to the December 2023 expanded agreement and milestones related to AI advancements in the GI Genius (搜索)™ platform. The company's cash position significantly improved from €50.3 million at the end of 2023, showcasing strong operational performance.
GI Genius™
The installed base of GI Genius (搜索)™ continued to grow in 2024. The U.S. FDA granted 510(k) clearance for the latest generation module 300 hardware, powered by Nvidia IGX technology. The latest iteration of Cosmo's polyp detection SaMD (Software as a Medical Device) features significantly improved performances and includes post-procedural insights generated by advanced AI.
Winlevi®
Winlevi®, the top-prescribed branded topical acne treatment in the U.S., has generated over 1.2 million prescriptions since its launch in 2021. Regulatory approvals in Singapore, Australia, and New Zealand in 2024 underscore its global growth, with an approval by EMA anticipated in H1 2025.
Breezula®
The Phase III clinical program for Breezula® in androgenetic alopecia (搜索) (AGA) in males is progressing on schedule, with top-line six-month results expected in 2025. Ongoing market research will support the strategic launch planning for this potential blockbuster drug.
Advancing Pipeline Programs
- Bile Acid Diarrhea: The Phase II proof-of-concept study was approved in the UK at the end of 2024, with the first patient expected to be enrolled by the end of January 2025. Bile Acid Diarrhea (BAD) affects an estimated 95 million people globally, with studies suggesting that approximately 30% of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) suffer from BAD.
- Distal Ulcerative Colitis: The Phase II study is progressing with active patient recruitment across 24 sites. Distal Ulcerative Colitis (Distal UC) affects an estimated 3.5 million people globally, with studies suggesting that approximately 70% of Ulcerative Colitis patients are experiencing Distal UC.
- Solid Tumors: The ongoing Phase I study evaluating safety and efficacy is progressing well. Following the completion of Part I of the study in H2 2025, the company plans to explore partnership opportunities for this asset.
Leadership Insights
Giovanni Di Napoli, CEO of Cosmo, stated, "2024 has been a transformative year for Cosmo, marked by innovation, achievement, and significant progress across all fronts. Through strategic investments and a commitment to operational excellence, we are driving growth and redefining market leadership."
Svetlana Sigalova, CFO, added, "Our robust cash position and debt-free balance sheet enable us to advance our pipeline and deliver value to patients and shareholders alike."